Compare MXL & IMVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MXL | IMVT |
|---|---|---|
| Founded | 2003 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.5B | 8.0B |
| IPO Year | 2009 | 2019 |
| Metric | MXL | IMVT |
|---|---|---|
| Price | $91.97 | $38.87 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 6 | 8 |
| Target Price | ★ $41.67 | $33.00 |
| AVG Volume (30 Days) | ★ 3.3M | 1.4M |
| Earning Date | 04-23-2026 | 05-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 46.08 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $478,596,000.00 | N/A |
| Revenue This Year | $22.10 | N/A |
| Revenue Next Year | $10.70 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $12.77 | $14.32 |
| 52 Week High | $128.30 | $41.23 |
| Indicator | MXL | IMVT |
|---|---|---|
| Relative Strength Index (RSI) | 50.24 | 60.24 |
| Support Level | $74.01 | $25.13 |
| Resistance Level | $105.27 | N/A |
| Average True Range (ATR) | 11.69 | 1.31 |
| MACD | -1.63 | -0.18 |
| Stochastic Oscillator | 27.41 | 34.95 |
MaxLinear Inc is a provider of radio frequency and mixed-signal integrated circuits for cable and satellite broadband communications, the connected home, and for data center, metro, and long-haul fiber networks. The company's radio frequency receiver products capture and process digital and analog broadband signals to be decoded for various applications. Its product options include both radio frequency receivers and radio frequency receiver systems-on-chips. The company's products enable the distribution and display of broadband video and data content in a wide range of electronic devices.
Immunovant Inc is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. Its focus is on developing IMVT-1402, a potential inhibitor of the neonatal fragment crystallizable receptor (FcRn), to address autoimmune diseases driven by high levels of pathogenic immunoglobulin G (IgG) antibodies. FcRn is involved in preventing the degradation of IgG antibodies, and inhibition of FcRn has been shown to reduce levels of total IgG and pathogenic IgG antibodies. The Company operates in a single operating segment and has one reportable segment, which includes all activities related to the discovery, development and manufacturing of its product candidates.